Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated strong financial fundamentals, with a 21% top-line growth in Q3, supported by a 13% increase in volume and a 5% rise in average selling prices, alongside achieving its highest cash collections in history in October. The company has notably expanded its sales force by approximately 50%, which is expected to enhance volume growth further, following a solid 19% year-over-year increase in kidney surveillance volumes reported in Q2'25. Additionally, CareDx achieved GAAP net income positivity and raised its revenue guidance, reflecting positive momentum that helped boost its stock by 10%.

Bears say

CareDx Inc. has reported Q3'25 testing volumes of 50,000, which, while representing a 13% year-over-year increase, fell short of expectations and experienced seasonal slowdowns. The company's shares have faced downward pressure, trading at a low multiple of 1.4 times projected revenues for 2026, significantly below historical averages and peers within the diagnostics sector. Additionally, ongoing management turnover and uncertainties surrounding the commercialization of new diagnostic solutions raise significant concerns over the company’s growth trajectory and competitive positioning in the market.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.